European Psychiatry
June 1, 2026
M. Pastre, F. Pereira, T. Gibert et al.
Introduction Treatment-resistant depression (TRD) remains a major clinical challenge, with limited efficacy of available therapies. Psilocybin, a serotonergic psychedelic, has shown promising antidepressant effects. As recent studies have shown altered default mode network activity following psilocybin administration, further neuroimaging research in clinical populations is needed to clarify...
European psychiatry : the journal of the Association of European Psychiatrists
August 26, 2025
Ismaël Conejero, Raquel Alvarez García, Alejandro Porras-Segovia et al.
2 citations
Esketamine has been shown to produce a major antidepressant response in patients with treatment-resistant depression (TRD). We evaluated the factors associated with achieving remission in these individuals. The study was carried out across four psychiatry departments in Madrid, Spain. Patients aged over 18 years were included if they received esketamine as an augmentation treatment for TRD....
Journal of Psychopharmacology
May 12, 2025
Clémentine Estric, Thomas Duron, Sarah Kabani et al.
10 citations
Psychedelics offer promising outcomes in psychiatry. However, the preparation of participants (set) and the environmental conditions of taking a psychedelic (setting) are not standardized. We describe the set and setting for therapeutic use of psychedelic drugs in people with psychiatric disorders. In this systematic review, articles were identified in the PubMed and Web of Science databases...
Current Psychiatry Reports
October 1, 2022
Damien Prouzeau, Ismaël Conejero, Peter L Voyvodic et al.
32 citations
We aim to provide an overview of the current state of knowledge about the efficacy of psilocybin in the treatment of depression, as well as its mechanisms of action. Psilocybin has a large, rapid, and persistent clinical effect in the treatment of resistant or end-of-life depression. Tolerance is good, with mild side effects limited to a few hours after dosing. The studies conducted to date...
Pharmaceuticals
November 24, 2021
Robertas Strumila, Bénédicte Nobile, Laura Korsakova et al.
35 citations
The available interventions for people who are at risk of suicide have limited efficacy. Recently, research on new mental health treatments has started to consider psychedelic compounds, particularly psilocybin, a molecule with a few thousand years of history of use in human societies. The possible effects of psilocybin on suicidal ideation and behaviors have not been specifically studied yet;...